BioSpace News Archive

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that top-line data from its Phase 2 study of lasofoxifene, its lead investigational drug, versus fulvestrant was accepted for a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022.

INVO Bioscience, Inc. announced that Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz, formally known as Hospital Universiti Kebangsaan Malaysia, based in Kuala Lumpur, Malaysia, is making IVC available for their patients.

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced it has raised $10M in Series B funding led by VCapital.

Benchling, the R&D Cloud powering the biotechnology industry, announced the appointment of new executive leadership to its engineering and field organizations.

Society for Science (the Society) and Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Thermo Fisher will be the new title sponsor of the Society’s middle school STEM (science, technology, engineering and math) competition, the nation’s premier STEM competition.

Cognesy Therapeutics, a recently established company developing a platform for the discovery of neuroplasticity-inducing drugs to treat a wide range of neuropsychiatric disorders, announced appointments of its senior leadership team, the company said today.

PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb.

Therapeutic Solutions International announced today filing with the Food and Drug Administration (FDA) an amendment to its currently open Phase III clinical trial requesting expansion of eligible patients with all patients suffering from Acute Respiratory Distress Syndrome (ARDS) regardless of cause.

Penumbra, Inc., a global healthcare company focused on innovative therapies, announced initial INSIGHT Registry data showing Penumbra’s RED® reperfusion catheters were successful in removing all clot types.

TandemAI today announced the appointment of Steve Swann, Ph.D., to the newly created position of Chief Scientific Officer.